Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the company’s IHL-42X for the treatment of Obstructive Sleep Apnoea (OSA). This Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in people with OSA who are intolerant, non-compliant or naïve to continuous positive airway pressure (CPAP).
Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
